RecruitingEarly Phase 1NCT07086794

Cocaine and Pentoxifylline (BED IN 47)

Targeting Immune Inflammation in Cocaine Use Disorder: A Human Laboratory Study With Pentoxifylline

Sponsor

William Stoops

Enrollment

30 participants

Start Date

Nov 10, 2025

Study Type

INTERVENTIONAL

Conditions

Cocaine Use Disorder

Summary

This will be a human laboratory study evaluating the influence of pentoxifylline treatment on the effects of cocaine. Supported by and included in the Helping to End Addiction Long-term® (HEAL) Initiative.

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Inclusion Criteria7

able to speak/read English,
not seeking treatment for drug use at the time of the study,
female or male between the ages of 18 and 55 years,
recent smoked or intravenous cocaine use verified by benzoylecgonine positive urine, as well as fulfillment of DSM-5 diagnostic criteria for CUD,
judged to be medically and psychiatrically healthy by study physicians other than the diagnosis for CUD at the time of screening,
ECG, read by a cardiologist, within normal limits,
females using an effective form of birth control and not pregnant or breastfeeding and 8) no known contraindications or allergies to pentoxifylline.

Exclusion Criteria9

unable to speak/read English,
seeking treatment for drug use,
under 18 years or over 55 years,
no recent smoked or intravenous cocaine use as indicated by benzoylecgonine negative urine and no DSM-5 diagnosis of CUD,
judged to be medically or psychiatrically unhealthy by study physicians at the time of screening,
ECG, read by a cardiologist, outside normal limits,
females not using an effective form of birth control or pregnant or breastfeeding,
contraindications or allergies to pentoxifylline, and
Self-reported history of head trauma, seizure, CNS tumors, or use of concomitant medications that lower seizure threshold, or first-degree family history of seizures.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.